Nevro Strengthens Leadership Team with the Appointment of David Caraway, MD, PhD as Chief Medical Officer
MENLO PARK, Calif., March 31, 2014 /PRNewswire/ -- Nevro, a growth stage medical device company focused on developing innovative, evidence based solutions in the neuromodulation space, announced today the appointment of Dr. David Caraway as its Chief Medical Officer.
Dr. Caraway will provide strategic direction and support the design, development, and adoption of cutting-edge therapies that aim to advance the neuromodulation field. He will also represent Nevro's mission and values in establishing a medical affairs function with global responsibility for generating and providing medical and scientific evidence on Nevro's products.
Dr. Caraway is a world renowned thought leader having spent over 20 years in neuromodulation, playing a key role in the development of the field and having held many leadership roles in major societies such as the North American Neuromodulation Society and the American Society of Interventional Pain Physicians. Additionally, Dr. Caraway has been a leader in regulatory, reimbursement, and evidence development in the field of neuromodulation through his involvement in the Relative Value Scale Update Committee (RUC), consulting on matters related to technological innovation, regulatory approvals and the design of numerous clinical studies. In these leadership roles, Dr. Caraway has focused on enhancing patient access to neuromodulation therapies, and improved patient outcomes.
Dr. Caraway also established and directed a thriving state of the art medical practice and brings vast experience as a clinical expert, thought leader and teacher having personally mentored many emerging luminaries in the field. Dr. Caraway has authored numerous peer-reviewed scientific publications and has served as editorial reviewer on several medical journals.
"The appointment of David Caraway as CMO underscores Nevro's continuing commitment to the neuromodulation space. We believe Nevro's innovations represent a significant advancement in the field and we continue to invest in accomplished leaders as a key to our growth," commented Michael DeMane, CEO.
In accepting this position, Dr. Caraway commented: "I'm excited to join a company that has built its foundation on delivering innovative products backed by clinical evidence. I believe innovation and evidence are the two biggest drivers for the future advancement of neuromodulation and for continued access of these effective therapies. I look forward to joining the Nevro team as they work to bring an innovative technology to market and seek to provide a very compelling therapy option for physicians and patients."
Dr. Caraway earned a Bachelor of Science degree in Chemical Engineering with Highest Distinction from the University of Virginia. He continued at his alma mater in the Medical Scientist Training Program under the auspices of the National Institutes of Health simultaneously earning a Medical Degree as well as a PhD in Biophysics. He completed his training in Anesthesiology and Pain Management at University of Virginia. He is currently the CEO and Medical Director of the Center for Pain Relief Tri-State, PLLC.
About the Senza system
Nevro's Senza® system delivers HF10™ therapy, an advanced spinal cord stimulation therapy which provides electrical pulses to the spinal cord at a rate up to 10,000 per second (10 kHz), as compared to traditional low-frequency SCS therapy, which usually deliver the electrical pulses at less than 100 pulses per second for chronic back- and leg-pain. The electrical pulses are conveyed by small electrodes placed in the epidural space and connected to a compact battery-powered generator implanted under the skin. The Senza system utilizes a rechargeable battery and has achieved a CE Mark labeling for a 10 year battery life.
The Senza system is authorized for sale in Europe and Australia and is supported by European data published in Pain Medicine and Neuromodulation: Technology at the Neural Interface. In the United States, the system is limited by federal law to investigational use only and is not available for sale.
Headquartered in Menlo Park, California, privately held Nevro is focused on becoming a leader in neuromodulation by developing innovative, evidence based solutions. The company pioneered high frequency stimulation for the treatment of chronic pain and other neurological disorders. Nevro's investors include Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Covidien Ventures, Johnson & Johnson Development Corporation, MPM Capital, New Enterprise Associates, Novo Ventures, and Three Arch Partners.
Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.
SOURCE Nevro Corp.